{"filing":{"accession_number":"0001140361-26-035091","cik":"0002081043","ticker":"ATAI","company_name":"AtaiBeckley Inc.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"ef20081348_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126035091/ef20081348_8k.htm"},"events":[{"id":30656,"run_id":28104,"accession_number":"0001140361-26-035091","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses material progress toward completion of a merger with Eli Lilly and Company. The Hart-Scott-Rodino antitrust waiting period expired on August 28, 2026, and regulatory clearances from the UK Competition and Markets Authority and Australian Competition and Consumer Commission have been obtained or are imminent. This represents a significant milestone in the consummation of a material acquisition that would result in AtaiBeckley becoming a wholly owned subsidiary of Eli Lilly.","company_name":"AtaiBeckley Inc.","ticker":"ATAI","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33314,"accession_number":"0001140361-26-035091","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses material progress toward completion of a merger with Eli Lilly and Company. The Hart-Scott-Rodino antitrust waiting period expired on August 28, 2026, and regulatory clearances from the UK Competition and Markets Authority and Australian Competition and Consumer Commission have been obtained or are imminent. This represents a significant milestone in the consummation of a material acquisition that would result in AtaiBeckley becoming a wholly owned subsidiary of Eli Lilly.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:40:04.814219+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33314,"accession_number":"0001140361-26-035091","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses material progress toward completion of a merger with Eli Lilly and Company. The Hart-Scott-Rodino antitrust waiting period expired on August 28, 2026, and regulatory clearances from the UK Competition and Markets Authority and Australian Competition and Consumer Commission have been obtained or are imminent. This represents a significant milestone in the consummation of a material acquisition that would result in AtaiBeckley becoming a wholly owned subsidiary of Eli Lilly.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:40:04.814219+00:00","company_name":"AtaiBeckley Inc.","ticker":"ATAI","filing_date":"2026-08-31"}]}